Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 30 | 2026AZ Looks to China for Latest Obesity Deal; January CHMP Meeting Highlights; Regeneron Q4 ’25 Earnings; Lilly Builds New Site in Pennsylvania; Novo Teases Super Bowl CommercialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Jan 29 | 2026Roche and Sanofi Q4 ’25 earnings; New Fractyl Revita DataPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Jan 28 | 2026Trulicity on Medicare Negotiation List; Novo Outspends Lilly on GLP-1RA Advertising; Ro’s GLP-1RA Super Bowl CommercialPurchase Blast
$599
Posted in: Dual/triple agonist, Other, Topics Jan 27 | 2026Roche Ph2 CT-388 Topline Data; Lilly Initiates Fourth Ph3 Eloralintide Trial; Arrowhead Initiates Ph1/2a ARO-DIMER-PA Study; Argo Doses First Patient in Ph2b siRNA Study; Myqorzo Available in US and Cytokinetics Partners with Olympic Gold Medalist for HCMPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 26 | 2026Novo’s Wegovy Pill Off to Quick Start; New Ph3b Retatrutide Study; Lilly Launches Obesity Campaign; Biomed Initiates Two Ph3 Quadruple Agonist Trials; Alveus Advances Obesity Asset; Afrezza Label Update; January CHMP AgendaPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, SGLT2i, Topics Jan 22 | 2026Novo Initiates Two Cagrisema Formulation/Device Trials; Lilly Initiates Third Ph3 Eloralintide Trial; FDA Approves Zepbound Kwikpen; Roche Increases Investment for Obesity Manufacturing Site; Abbott Q4 ’25 Earnings; CORXEL Closes $287M Series D1 Funding; Sesame Partners with Novo for Wegovy PillPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 20 | 2026Roche Initiates Ph3 Obesity Program; Novo Partners for T1DM and Launches New Ozempic Campaign; Ascletis Selects Obesity Candidate; BioAge Expands NLRP3i Development; Richard DiMarchi Featured in IU CommercialPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Jan 16 | 2026Early Wegovy Pill Prescription Trends; InterAx and Alveus Drug Discovery PartnershipPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i, Topics Jan 15 | 2026JPM 2026 Day 4: IVA, JNGHF, LXRX, BMEA, ESPR; FDA Delays CNPV ApprovalsPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jan 14 | 2026JPM 2026 Day 3: ZLDPF, ABBV, SANA, PODD; Jazz to Sell PRV; Novo Initiates Amycretin Ph3 Program; Madrigal Initiates New Ph2 Resmetirom MASH Study; Sandoz Confirms EC Approval of OndibtaPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 13 | 2026JPM 2025 Day 2: LLY, NVO, AMGN, VKTX, AZN, MRK, IONS; Obesity Association Debuts Standards of Care for Obesity MedicationsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jan 12 | 2026JPM 2026 Day 1: DXCM, ARWR, NVS, ALNY, PFE, SNY, CYTK, MDT, MDGL, REGN; Skye 2026 Corporate Outlook; BioAge NLRP3i Ph1 Data; Kailera Ph3 KaiNETIC Program UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 09 | 2026Madrigal Licenses MASH Assets from Pfizer; Wegovy Pill Available on Amazon; New BI MASH Asset; Alveus Launches as Clinical-Stage Biotech; Zealand Partners for AI Drug Discovery; Lilly Expands TuneLabPurchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, Topics Jan 08 | 2026Antag Ph1 Obesity Data; Lilly Zepbound+Taltz PsA Combination Data; Rani Initiates Ph1 Dual Agonist Study; Viking Completes Ph1 VK2735 Maintenance Study Enrollment; Gordian and Pfizer Partner for Obesity Drug Discovery; MannKind Provides 2026 Business UpdatesPurchase Blast
$599
Posted in: Other, Topics Jan 07 | 2026Lilly Initiates Second Ph3 Eloralintide Trial; Lilly Acquires Ventyx; Monte Rosa Interim Ph1 Data; Corsera Series A FundingPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 07 | 2026Arrowhead Ph1/2 RNAi-Based Obesity Results; MindRank Ph3 Oral GLP-1RA Program; Altimmune Receives Breakthrough Therapy Designation; Nimbus and Lilly Partner for Obesity; Roche and Structure Patent Agreement; Novo Debuts Report on America’s Obesity EpidemicPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jan 06 | 2026Holiday Hangover: Novo Launches Wegovy Pill; Additional Companies Engage in MFN Deals; Pfizer Initiates Ph3 Obesity Program of MET097i; and MorePurchase Blast
$599
Posted in: Dual/triple agonist, Topics Dec 19 | 2025Altimmune Topline Ph2 Pemvidutide MASH DataPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 18 | 2025Lilly’s Ph3 ATTAIN-MAINTAIN Results; Orforglipron Filed; Novo Files Cagrisema and Receives FDA Warning Letter; Merck to Receive CNPV; SAB BIO Pivotal Ph2b T1DM Trial; Sagimet Enters Agreement for ResmetiromPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 17 | 2025Kailera Initiates H2H Study Vs. Semaglutide; Structure Initiates Ph1 Amylin Study; Rona Unveils Bivalent siRNA; Lilly Partners for Obesity Drug Discovery and Initiates Brenipatide Ph2 Bipolar Trial; Enveda Receives IND; ICER Obesity ReportPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
